Short answer
Biomarin Pharmaceutical Inc (BMRN) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.0B (up 32.0% year over year) with net income of −$123M.
Q3 2026 key financials · XBRL
- Revenue
- $1.0B
- +32.0% YoY · +3.5% QoQ
- Net income
- −$123M
- −299.5% YoY · −374.4% QoQ
- Operating margin
- -8.0%
- EPS (diluted)
- −$0.63
- −320.0% YoY · −373.9% QoQ
Source: XBRL data from the Biomarin Pharmaceutical Inc (BMRN) Q3 2026 10-Q on SEC EDGAR. USD.
Biomarin Pharmaceutical Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $1,024.6M, up $248.5M YoY from $776.1M
- Gross margin 80.0% vs 81.9% YoY, pressured by lower-margin product mix
- Best performer: GALAFOLD revenue $151.8M, worst: NAGLAZYME revenue $107.8M, down $14.2M YoY
- Cash and investments $736.0M, down $1,316.8M from December 31, 2025; operating cash flow $577.0M
- Near-term headwinds: inconsistent government orders, macroeconomic volatility, $70.0M BMN 450 upfront payment in fourth quarter, higher debt expense
Risk Factors
- Acquisition integration risk: April 2026 Amicus and August 2026 Alesta acquisitions expanded operations and increased execution complexity
- Liquidity risk: $736.0 million cash versus $4.2 billion debt, including 2027 Notes maturing in May 2027
- Regulatory pricing risk: IRA Medicare negotiations, inflation rebates, and EU HTA regulation increase downward pricing pressure
- Trade risk: 100% tariffs on certain patented pharmaceuticals and ingredients beginning September 29, 2026
- Manufacturing risk: GALAFOLD and POMBILITI rely on single-source third-party manufacturers
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.